147 related articles for article (PubMed ID: 36795452)
1. C1q helps AML to disseminate and resist.
Lengliné E
Blood; 2023 Feb; 141(7):691-692. PubMed ID: 36795452
[No Abstract] [Full Text] [Related]
2. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.
Yang LX; Zhang CT; Yang MY; Zhang XH; Liu HC; Luo CH; Jiang Y; Wang ZM; Yang ZY; Shi ZP; Yang YC; Wei RQ; Zhou L; Mi J; Zhou AW; Yao ZR; Xia L; Yan JS; Lu Y
Blood; 2023 Feb; 141(7):766-786. PubMed ID: 36322939
[TBL] [Abstract][Full Text] [Related]
3. [The role of hematopoietic stem cell transplantation for acute myeloid leukemia].
Kato K
Rinsho Ketsueki; 2015 Oct; 56(10):1950-9. PubMed ID: 26458433
[TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia: A Review.
Pelcovits A; Niroula R
R I Med J (2013); 2020 Apr; 103(3):38-40. PubMed ID: 32236160
[TBL] [Abstract][Full Text] [Related]
5. Miliary leukemia cutis as extramedullary relapse of KMT2A rearranged pediatric AML.
Muratore E; Belotti T; Gottardi F; Sagramoso C; Prete A; Masetti R
Leuk Lymphoma; 2023; 64(8):1494-1496. PubMed ID: 37221837
[No Abstract] [Full Text] [Related]
6. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Kabra M; Margotto L; Manuguid F
Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
[TBL] [Abstract][Full Text] [Related]
7. Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor.
Sturfelt G; Lenhoff S; Sallerfors B; Nived O; Truedsson L; Sjöholm AG
Ann Rheum Dis; 1996 Sep; 55(9):638-41. PubMed ID: 8882135
[TBL] [Abstract][Full Text] [Related]
8. C1q+ macrophages: passengers or drivers of cancer progression.
Revel M; Sautès-Fridman C; Fridman WH; Roumenina LT
Trends Cancer; 2022 Jul; 8(7):517-526. PubMed ID: 35288093
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
[TBL] [Abstract][Full Text] [Related]
10. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration.
Jiao H; Rutar M; Fernando N; Yednock T; Sankaranarayanan S; Aggio-Bruce R; Provis J; Natoli R
Mol Neurodegener; 2018 Aug; 13(1):45. PubMed ID: 30126455
[TBL] [Abstract][Full Text] [Related]
11. Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet.
Fink A; Hung E; Singh I; Ben-Neriah Y
Eur J Immunol; 2022 Jan; 52(1):34-43. PubMed ID: 34648664
[TBL] [Abstract][Full Text] [Related]
12. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.
Peterlin P; Renneville A; Ben Abdelali R; Nibourel O; Thomas X; Pautas C; de Botton S; Raffoux E; Cayuela JM; Boissel N; Terré C; Celli-Lebras K; Castaigne S; Preudhomme C; Gardin C; Dombret H
Haematologica; 2015 May; 100(5):e196-9. PubMed ID: 25552703
[No Abstract] [Full Text] [Related]
13. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
Ferraro F; Miller CA; Christensen KA; Helton NM; O'Laughlin M; Fronick CC; Fulton RS; Kohlschmidt J; Eisfeld AK; Bloomfield CD; Ramakrishnan SM; Day RB; Wartman LD; Uy GL; Welch JS; Christopher MJ; Heath SE; Baty JD; Schuelke MJ; Payton JE; Spencer DH; Rettig MP; Link DC; Walter MJ; Westervelt P; DiPersio JF; Ley TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34845035
[TBL] [Abstract][Full Text] [Related]
14. The evolving paradigm of prognostic factors in AML: Introduction to the Acute Leukemia Forum 2010.
Rowe JM
Best Pract Res Clin Haematol; 2010 Dec; 23(4):453-6. PubMed ID: 21130406
[No Abstract] [Full Text] [Related]
15. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
16. [Roles of mTORC1 in acute myeloid leukemia].
Hoshii T; Hirao A
Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
[TBL] [Abstract][Full Text] [Related]
17. Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants.
Tarlock K; Meshinchi S
Pediatr Clin North Am; 2015 Feb; 62(1):75-93. PubMed ID: 25435113
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significances of circulating immune complexes in hematologic disorders--detection by C1q deviation test and anti-antibody inhibition test].
Yasuda M; Nobunaga M; Sakai K; Motomura S; Ibayashi H; Kozuru M
Rinsho Ketsueki; 1983 Apr; 24(4):448-55. PubMed ID: 6604173
[No Abstract] [Full Text] [Related]
19. Progress in acute myeloid leukemia.
Kadia TM; Ravandi F; O'Brien S; Cortes J; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):139-51. PubMed ID: 25441110
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
